![Traveling with cancer. Retired couple in front of cruise ship holding map](https://netrf.org/wp-content/uploads/2019/07/TravelingwithNETs-300x150.jpg)
Travel Tips for Cancer Patients
Neuroendocrine cancer patients traveling for pleasure, business, or cancer treatment, may need to consider a few extra details to ensure travel goes smoothly. These travel
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Neuroendocrine cancer patients traveling for pleasure, business, or cancer treatment, may need to consider a few extra details to ensure travel goes smoothly. These travel
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET
Neuroendocrine cancer community faces loss. Carol Branaman, vice chair and former chair of NETRF, passes from neuroendocrine cancer.
From a place of discouragement after being diagnosed with a NET in June 2018, Susan Garrett of Roxboro, NC, saw a news story on WRAL
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Increasing Precision in Cancer Cell Death to Prevent Metastasis In housework and lawn work, it is important to have the right tool for the job.
Mark A. Lewis, MD, Director of Gastrointestinal Oncology, Intermountain Healthcare, Utah, has joined the Board of Directors for the Neuroendocrine Tumor Research Foundation. Dr. Lewis,
NETRF given the highest ranking for financial responsibility and transparency by leading nonprofit rating program, GoldStar.